These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

201 related items for PubMed ID: 32416325

  • 1. Somatostatin receptor profile in pituitary thyrotroph adenomas.
    Thodou E, Kontogeorgos G.
    Clin Neurol Neurosurg; 2020 Aug; 195():105865. PubMed ID: 32416325
    [Abstract] [Full Text] [Related]

  • 2. Somatostatin receptor subtypes mRNA in TSH-secreting pituitary adenomas: a case showing a dramatic reduction in tumor size during short octreotide treatment.
    Horiguchi K, Yamada M, Umezawa R, Satoh T, Hashimoto K, Tosaka M, Yamada S, Mori M.
    Endocr J; 2007 Jun; 54(3):371-8. PubMed ID: 17420609
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
    Pawlikowski M, Lawnicka H, Pisarek H, Kunert-Radek J, Radek M, Culler MD.
    J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
    [Abstract] [Full Text] [Related]

  • 5. Expression of somatostatin receptor (SSTR) subtypes in pituitary adenomas: quantitative analysis of SSTR2 mRNA by reverse transcription-polymerase chain reaction.
    Murabe H, Shimatsu A, Ihara C, Mizuta H, Nakamura Y, Nagata I, Kikuchi H, Nakao K.
    J Neuroendocrinol; 1996 Aug; 8(8):605-10. PubMed ID: 8866248
    [Abstract] [Full Text] [Related]

  • 6. Somatostatin receptor subtype gene expression in pituitary adenomas.
    Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT, Klibanski A.
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115
    [Abstract] [Full Text] [Related]

  • 7. Somatostatin receptors in pituitary and development of somatostatin receptor subtype-selective analogs.
    Shimon I.
    Endocrine; 2003 Apr; 20(3):265-9. PubMed ID: 12721506
    [Abstract] [Full Text] [Related]

  • 8. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion.
    Zatelli MC, Piccin D, Tagliati F, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Culler MD, degli Uberti EC.
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2797-802. PubMed ID: 12788890
    [Abstract] [Full Text] [Related]

  • 9. Expression of somatostatin receptor subtypes in human pituitary adenomas -- immunohistochemical studies.
    Pisarek H, Pawlikowski M, Kunert-Radek J, Radek M.
    Endokrynol Pol; 2009 Jun; 60(4):240-51. PubMed ID: 19753537
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors.
    Panetta R, Patel YC.
    Life Sci; 1995 Jun; 56(5):333-42. PubMed ID: 7530798
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.
    Florio T, Thellung S, Corsaro A, Bocca L, Arena S, Pattarozzi A, Villa V, Massa A, Diana F, Schettini D, Barbieri F, Ravetti JL, Spaziante R, Giusti M, Schettini G.
    Clin Endocrinol (Oxf); 2003 Jul; 59(1):115-28. PubMed ID: 12807513
    [Abstract] [Full Text] [Related]

  • 16. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone-secreting adenoma cells in vitro.
    Tulipano G, Bonfanti C, Milani G, Billeci B, Bollati A, Cozzi R, Maira G, Murphy WA, Poiesi C, Turazzi S, Giustina A.
    Neuroendocrinology; 2001 May; 73(5):344-51. PubMed ID: 11399907
    [Abstract] [Full Text] [Related]

  • 17. Does the response of GH-secreting pituitary adenomas to octreotide depend on the cellular localization of the somatostatin receptor subtypes SSTR2 and SSTR5?
    Pisarek H, Pawlikowski M, Kunert-Radek J, Winczyk K.
    Endokrynol Pol; 2010 May; 61(2):178-81. PubMed ID: 20464704
    [Abstract] [Full Text] [Related]

  • 18. Evidence for differential effects of selective somatostatin receptor subtype agonists on alpha-subunit and chromogranin a secretion and on cell viability in human nonfunctioning pituitary adenomas in vitro.
    Zatelli MC, Piccin D, Bottoni A, Ambrosio MR, Margutti A, Padovani R, Scanarini M, Taylor JE, Culler MD, Cavazzini L, degli Uberti EC.
    J Clin Endocrinol Metab; 2004 Oct; 89(10):5181-8. PubMed ID: 15472224
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. SSTR2 is the functionally dominant somatostatin receptor in human pancreatic β- and α-cells.
    Kailey B, van de Bunt M, Cheley S, Johnson PR, MacDonald PE, Gloyn AL, Rorsman P, Braun M.
    Am J Physiol Endocrinol Metab; 2012 Nov 01; 303(9):E1107-16. PubMed ID: 22932785
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.